Biogen Reports Quarterly Revenues of $3.1 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Biogen (BIIB) PT Raised to $355 at Leerink Partners
October 25, 2017 7:29 AM EDTLeerink Partners raised its price target on Biogen (NASDAQ: BIIB) to $355.00 (from $351.00) while maintaining a Market Perform rating.
... MoreSPINRAZA Confusion Creates a Buying Opportunity in Biogen (BIIB) - Stifel
October 24, 2017 11:58 AM EDTStifel analyst Thomas Shrader reiterated a Buy rating and $430 price target on Biogen (NASDAQ: BIIB) saying SPINRAZA confusion is an opportunity.
"Some SPINRAZA confusion based in flattish U.S. sales in the face of 75% patient number increase," Shrader commented. "We expect the 2Q revenue... More
Biogen (BIIB) Tops Q3 EPS by 61c
October 24, 2017 7:00 AM EDTBiogen (NASDAQ: BIIB) reported Q3 EPS of $6.31, $0.61 better than the analyst estimate of $5.70. Revenue for the quarter came in at $3.1 billion versus the consensus estimate of $3.03 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
... More